Cargando…

Validation of multiple myeloma risk stratification indices in routine clinical practice: Analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies

This study used data from the Czech Myeloma Group Registry of Monoclonal Gammopathies to validate the International Myeloma Working Group (IMWG) and revised International Staging System (R‐ISS) indices for risk stratification in patients with multiple myeloma (MM) in clinical practice. Patients were...

Descripción completa

Detalles Bibliográficos
Autores principales:	Radocha, Jakub, Maisnar, Vladimír, Pour, Luděk, Špička, Ivan, Minařík, Jiři, Szeligová, Lenka, Pavlíček, Petr, Jungová, Alexandra, Krejčí, Marta, Pika, Tomáš, Straub, Jan, Brožová, Lucie, Stejskal, Lukáš, Heindorfer, Adriana, Jindra, Pavel, Kessler, Petr, Mikula, Peter, Sýkora, Michal, Wróbel, Marek, Jarkovský, Jiří, Hájek, Roman
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Cancer Prevention
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6089168/ https://www.ncbi.nlm.nih.gov/pubmed/29931775 http://dx.doi.org/10.1002/cam4.1620

Ejemplares similares

OAB-046: COVID-19 infection in multiple myeloma patients – retrospective analysis of 371 Czech patients
por: Radocha, Jakub, et al.
Publicado: (2021)

Identification of patients at high risk of secondary extramedullary multiple myeloma development
por: Stork, Martin, et al.
Publicado: (2021)

P1294: REAL-WORLD OUTCOMES OF 2149 NEWLY DIAGNOSED TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS
por: Popková, Tereza, et al.
Publicado: (2023)

Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas
por: Stork, Martin, et al.
Publicado: (2022)

Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice
por: Minarik, Jiri, et al.
Publicado: (2021)

Ixazomib, Lenalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice: Extended Follow-Up Analysis and the Results of Subsequent Therapy
por: Minarik, Jiri, et al.
Publicado: (2022)

Subcutaneous Bortezomib in Multiple Myeloma Patients Induces Similar Therapeutic Response Rates as Intravenous Application But It Does Not Reduce the Incidence of Peripheral Neuropathy
por: Minarik, Jiri, et al.
Publicado: (2015)

Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients – real world evidence analysis
por: Stork, Martin, et al.
Publicado: (2023)

Clinical characteristics and outcomes in risk-stratified patients with smoldering multiple myeloma: data from the Czech Republic Registry of Monoclonal Gammopathies
por: Sandecka, Viera, et al.
Publicado: (2023)

P967: TUMOR BURDEN AS A CRITICAL PROGNOSTIC FACTOR OF PRIMARY EXTRAMEDULLARY DISEASE
por: Vlachová, M., et al.
Publicado: (2022)

Prognostic Value of Hepatocyte Growth Factor, Syndecan-1, and Osteopontin in Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance
por: Minarik, Jiri, et al.
Publicado: (2012)

Circulating exosomal long noncoding RNA PRINS—First findings in monoclonal gammopathies
por: Sedlarikova, Lenka, et al.
Publicado: (2018)

Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data
por: Campioni, M., et al.
Publicado: (2019)

Clinical implication of centrosome amplification and expression of centrosomal functional genes in multiple myeloma
por: Dementyeva, Elena, et al.
Publicado: (2013)

Development and validation of a novel risk stratification algorithm for relapsed multiple myeloma
por: Hájek, Roman, et al.
Publicado: (2019)

Centrosome associated genes pattern for risk sub-stratification in multiple myeloma
por: Kryukov, Fedor, et al.
Publicado: (2016)

Dynamics of tumor‐specific cfDNA in response to therapy in multiple myeloma patients
por: Vrabel, David, et al.
Publicado: (2019)

Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study
por: Cowan, Annie, et al.
Publicado: (2023)

LncRNAs LY86-AS1 and VIM-AS1 Distinguish Plasma Cell Leukemia Patients from Multiple Myeloma Patients
por: Bútová, Romana, et al.
Publicado: (2021)

Mutation landscape of multiple myeloma measurable residual disease: identification of targets for precision medicine
por: Zátopková, Martina, et al.
Publicado: (2022)

Whole-genome optical mapping of bone-marrow myeloma cells reveals association of extramedullary multiple myeloma with chromosome 1 abnormalities
por: Kriegova, Eva, et al.
Publicado: (2021)

Serum protein fingerprinting by PEA immunoassay coupled with a pattern-recognition algorithms distinguishes MGUS and multiple myeloma
por: Schneiderova, Petra, et al.
Publicado: (2016)

Immunomodulatory Agents for Multiple Myeloma
por: Minařík, Jiří, et al.
Publicado: (2022)

The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma
por: Mikulasova, Aneta, et al.
Publicado: (2017)

A rare case of bifocal, extramedullary and hyposecretory relapse of multiple myeloma
por: Minarik, Jiri, et al.
Publicado: (2021)

Chromothripsis 18 in multiple myeloma patient with rapid extramedullary relapse
por: Smetana, Jan, et al.
Publicado: (2018)

Proteasome inhibitors – molecular basis and current perspectives in multiple myeloma
por: Kubiczkova, Lenka, et al.
Publicado: (2014)

Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma
por: Besse, Lenka, et al.
Publicado: (2015)

Involvement of Small Non-Coding RNA and Cell Antigens in Pathogenesis of Extramedullary Multiple Myeloma
por: Vlachová, Monika, et al.
Publicado: (2022)

Plasmacytoid Dendritic Cells in Patients with MGUS and Multiple Myeloma
por: Knight, Andrea, et al.
Publicado: (2021)

P876: ANCHOR (OP-104): MELFLUFEN PLUS DEXAMETHASONE AND DARATUMUMAB OR BORTEZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA—FINAL EFFICACY AND SAFETY RESULTS
por: Miguel, Enrique Maria Ocio San, et al.
Publicado: (2023)

Multiple Myeloma with Biclonal Gammopathy Accompanied by Prostate Cancer
por: Kim, Nae Yu, et al.
Publicado: (2011)

A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma
por: Hajek, Roman, et al.
Publicado: (2020)

Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study
por: Dimopoulos, Meletios, et al.
Publicado: (2018)

Outcome of COVID-19 infection in 50 multiple myeloma patients treated with novel drugs: single-center experience
por: Krejci, Marta, et al.
Publicado: (2021)

New Markers of Renal Failure in Multiple Myeloma and Monoclonal Gammopathies
por: Woziwodzka, Karolina, et al.
Publicado: (2020)

Autoimmune manifestations in patients with multiple myeloma and monoclonal gammopathy of undetermined significance()
por: Shimanovsky, Alexei, et al.
Publicado: (2016)

P34 LIGHTHOUSE (OP-108): MELFLUFEN PLUS DARATUMUMAB (DARA) AND DEXAMETHASONE (DEX) VERSUS DARA IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) REFRACTORY TO AN IMMUNOMODULATORY DRUG (IMID) AND A PROTEASOME INHIBITOR (PI) OR HAD RECEIVED ≥3 PRIOR LINES OF THERAPY INCLUDING AN IMID AND A PI
por: Mateos, M, et al.
Publicado: (2023)

Necessity of flow cytometry assessment of circulating plasma cells and its connection with clinical characteristics of primary and secondary plasma cell leukaemia
por: Bezdekova, Renata, et al.
Publicado: (2021)

P944: REAL-WORLD PATIENT CHARACTERISTICS AND SURVIVAL OUTCOMES OF LENALIDOMIDE REFRACTORY VS. LENALIDOMIDE EXPOSED RRMM PATIENTS IN THE HONEUR FEDERATED DATA NETWORK
por: Spicka, Ivan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_o6r564eihe7h46quf43sb7e9at